Avicenna Alliance: enhanced knowledge, improved decisions, better outcomes
FULL MENU

The potential of in silico approaches to streamline drug development

The potential of in silico approaches to streamline drug development

BACK

The potential of in silico approaches to streamline drug development

This position paper highlights the potential of in silico medicine, using computational modelling and simulation to aid drug discovery, development, and delivery. It calls for adaptation of in silico technology to be a standard practice to complement in vivo and in vitro approaches in healthcare through a collaborative ecosystem of stakeholders.

The application of in silico methods before animal testing or clinical trials to obtain insights can inform decision making and thus optimise clinical trial design and patient safety. In silico methods have been suggested to complement traditional evidence with digital evidence and therefore to reduce time, cost, and environmental footprint of the regulatory approval process. However, the impact of in silico methods in regulatory decision-making and post-market surveillance remains limited. There is a strong need to develop industrial infrastructure and regulatory framework to actively incorporate CM&Sto foster medical innovation and overcome current socio-economic and technological barriers in the drug development process. We invite all the stakeholders to join arms to promote adequate use of these methods.


Download

NEWS

News Welcome on Board, Hemolens Diagnostics!

Welcome on Board, Hemolens Diagnostics!

We are delighted to welcome Hemolens Diagnostics as a new member of the Avicenna Alliance!

News Poll on Computer Modelling & Simulation

Poll on Computer Modelling & Simulation

The Avicenna Clinical Deployment Task Force, led by Co-Chairs Erica Beaucage-Gauvreau & René Bombien, is engaged to grow a network of professionals with expertise in clinical applications of in silico methodologies, to foster collaboration and knowledge exchange.

News April 8th - Avicenna Webinar on ERAMET: Advancing Orphan & Paediatric Drug Development

April 8th - Avicenna Webinar on ERAMET: Advancing Orphan & Paediatric Drug Development

Join Next Avicenna Webinar on ERAMET: Advancing Orphan & Paediatric Drug Development! The EU-funded ERAMET project is transforming how orphan and paediatric medicines are developed. By integrating advanced Computational Modelling & Simulation (CM&S) techniques with real-world data, ERAMET is building a transparent ecosystem to support both medicine developers and regulators.

Sign up for our monthly newsletter!

Sign up for our monthly newsletter!

Fill in the fields you find below

Avicenna Alliance is an initiative of:

Avicenna VPH

© 2018-2025 Avicenna Alliance | powered by We Berry